Interpace Biosciences, Inc. (IDXG) — SEC Filings
Interpace Biosciences, Inc. (IDXG) — 27 SEC filings. Latest: 10-K (Mar 30, 2026). Includes 12 8-K, 6 10-Q, 3 10-K.
View Interpace Biosciences, Inc. on SEC EDGAR
Overview
Interpace Biosciences, Inc. (IDXG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Interpace Biosciences, Inc. (IDXG) is a molecular diagnostic company that experienced a significant business change in 2025 due to the Center for Medicare and Medicaid Services (CMS) ceasing reimbursement for its PancraGEN test on April 24, 2025, leading to its discontinuance by May 2, 2025. This st
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 3 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Interpace Biosciences, Inc. is neutral.
Filing Type Overview
Interpace Biosciences, Inc. (IDXG) has filed 3 10-K, 12 8-K, 6 10-Q, 2 10-K/A, 2 SC 13D/A, 1 DEF 14A, 1 SC 13G/A with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of IDXG's 26 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Douglas M. Singer
Industry Context
The global esoteric molecular diagnostics market is substantial, valued at $29.6 billion in 2025 and projected to reach $75.9 billion by 2034 with an 11.12% CAGR. This growth is driven by advancements in personalized medicine and the need for more accurate cancer risk assessment. Interpace Biosciences operates within this dynamic market, focusing on thyroid cancer diagnostics, an area estimated to be worth approximately $300 million annually.
Top Tags
8-k (4) · 10-Q (4) · amendment (4) · financial-reporting (4) · Biotechnology (3) · financials (3) · Molecular Diagnostics (2) · SEC Filing (2) · restructuring (2) · disposal (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Global esoteric molecular diagnostics market value | $29.6 billion | in 2025, projected to grow to $32.6 billion in 2026 |
| Compound Annual Growth Rate (CAGR) | 11.12% | for the global esoteric molecular diagnostics market from 2025 to 2034 |
| Estimated annual market for endocrine (thyroid) cancer assays | $300 million | based on current patient population and reimbursement rates |
| Date CMS ceased PancraGEN reimbursement | 2025-04-24 | led to discontinuance of the test |
| Date PancraGEN testing specimens were no longer accepted | 2025-05-02 | marking the full discontinuance of the test |
| Date IDXG common stock was removed from OTCQX | 2025-08-18 | following delisting from Nasdaq |
| Shares of common stock issued and outstanding | 27,700,904 | as of March 20, 2026 |
| Aggregate market value of common stock held by non-affiliates | $2,631,295 | on June 30, 2025 |
| Approximate reflex rate to ThyraMIR v2 | 85% | when ThyGeNEXT identifies mutations |
| Percentage of indeterminate thyroid nodules proving benign after surgery | 77% | according to a 2011 study by Wang, et al. |
| Net Revenue | $29.504M | Decreased from $34.515 million for the nine months ended September 30, 2024, a 14.5% decline. |
| Net Income | $1.918M | Decreased from $4.821 million for the nine months ended September 30, 2024, a 60.2% decline. |
| Cash and Cash Equivalents | $1.423M | As of September 30, 2025, down from $1.461 million at December 31, 2024. |
| Severance and Related Costs | $0.7M | Incurred for the nine months ended September 30, 2025, due to the Restructuring Plan. |
| Term Loan Outstanding | $1.0M | Balance with BroadOak at September 30, 2025. |
Frequently Asked Questions
What are the latest SEC filings for Interpace Biosciences, Inc. (IDXG)?
Interpace Biosciences, Inc. has 27 recent SEC filings from Feb 2024 to Mar 2026, including 12 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IDXG filings?
Across 27 filings, the sentiment breakdown is: 3 bearish, 23 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Interpace Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Interpace Biosciences, Inc. (IDXG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Interpace Biosciences, Inc.?
Key financial highlights from Interpace Biosciences, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IDXG?
The investment thesis for IDXG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Interpace Biosciences, Inc.?
Key executives identified across Interpace Biosciences, Inc.'s filings include Douglas M. Singer.
What are the main risk factors for Interpace Biosciences, Inc. stock?
Of IDXG's 26 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Interpace Biosciences, Inc.?
Forward guidance and predictions for Interpace Biosciences, Inc. are extracted from SEC filings as they are enriched.